anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemical and pharmaceutical industry. SUBSTANCE: tape is manufactured from thin and elastic reticulate, porous, fibrous or transparent film materials, adhesive being acrylic glue with viscosity 5-3 thousand mPa.s or rubber glue without fillers with viscosity 5-20 thousand mPa.s. Adhesive is applied on inadhesive transferring paper by doctor technique leaving gap of 20 to 100 mcm between ledge of spreading knife and paper. Drying is accomplished by multi-step lowering of temperature of heated air maintaining each temperature level for 1 to 5 min. Adhesive layer dried to moisture content 15% is joined to support and pressed at pressure at pressure rolls 3-6 atm. Resulting ensemble is wound and kept during 2-3 days, while adhesive layer of dried glue transfers onto support providing satisfactory adhesion to material. Then, material consisting of support, adhesive, and inadhesive coating (release layer) is cut into pieces with required dimensions, which are ready to use and put over skin by their adhesive layer. EFFECT: increased viability and avoided irritation for human skin. 3 cl
Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
<P>PROBLEM TO BE SOLVED: To provide a novel analgesic that shows effective action and reduced adverse effects, e.g. an analgesic that does not induce any gastrointestinal disorders associated with analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs).  <P>SOLUTION: The analgesic comprises a RXR agonist as an active ingredient. The RXR agonist used as the active ingredient exerts analgesic effect through an action mechanism other than inhibition of cyclooxygenase (COX) which the nonsteroidal anti-inflammatory drugs (NSAIDs) has. Unlike the nonsteroidal anti-inflammatory drugs (NSAIDs), which are known to induce gastrointestinal disorders by inhibiting COX, the RXR agonist do not act on COX. Thus, the analgesic comprising the RXR agonist as the active ingredient is an excellent analgesic having few adverse effects.  <P>COPYRIGHT: (C)2011,JPO&INPIT
This study will evaluate the effects of the Adherence Readiness Program (ARP) intervention on the primary outcomes of dose-taking HIV antiretroviral (ART) adherence and undetectable HIV viral load in a multi-site randomized controlled trial. The ARP is based on the Information Motivation Behavioral skills (IMB) model of behavior change and includes (1) brief pill taking practice trials for enhancing pre-treatment adherence counseling and providing a behavioral criterion for determining adherence readiness and the start of treatment, and (2) a performance driven dose regulation mechanism to tailor the amount of counseling (from pre-treatment through the full course of treatment) to the individual needs of the patient and conserve limited resources. Participants will be randomized to receive either the ARP (adherence counseling sessions) or usual care. Primary assessments will be administered at screening and every 6 months after ART initiation over a 24-month follow-up, making it one of the few studies to examine intervention effects longer than one year. Secondary outcomes include dose-timing adherence and CD4 count. If effective, the ARP will provide clinicians with an intervention that (1) informs providers and patients when the patient is ready to adhere well and start treatment, (2) enhances adherence readiness from the outset of treatment through the full course of therapy, and (3) tailors the amount of adherence support based on individual patient need and performance, thus more efficiently using clinic resources, fostering better acceptance from providers and patients, and increasing the likelihood of successful program adoption and dissemination. This emphasis on efficient use of resources will be complemented by a cost-effectiveness analysis to further inform policy decisions regarding the transportability of the intervention and its potential for more wide scale use and sustainability if effective.
OBJECTIVES: Antiseptics such as chlorhexidine gluconate (CHG) and octenidine dihydrochloride (OCT) are frequently used in hospitals to prevent and control the transmission of meticillin-resistant Staphylococcus aureus (MRSA). Given the increasing prevalence of reduced CHG susceptibility of MRSA, there are concerns about the possibility of reduced OCT susceptibility. This study evaluated the prevalence of reduced CHG and OCT susceptibility over 3 years, and assessed the association between OCT exposure and reduced OCT susceptibility in MRSA.
METHODS: MRSA isolates from inpatients who acquired MRSA in an extended-care facility between 2019 and 2021 were included in antiseptic susceptibility testing. Inpatients were exposed to universal daily CHG bathing from January to September 2019, and universal daily OCT bathing after October 2019. The minimum inhibitory concentrations (MICs) of CHG and OCT were determined using the broth microdilution method. Multi-variable logistic regression was used to assess if OCT exposure was independently associated with reduced OCT susceptibility.
RESULTS: Of 186 isolates, 179 (96%) had reduced CHG susceptibility (MIC ≥4 mg/L) and 46 (25%) had reduced OCT susceptibility (MIC ≥2 mg/L). Reduced OCT susceptibility rates were 26.9%, 13.8% and 14.3% in 2019, 2020 and 2021, respectively. Reduced CHG susceptibility rates were 95.4%, 100% and 95.9% in 2019, 2020 and 2021, respectively. OCT exposure was not associated with reduced OCT susceptibility (adjusted odds ratio 0.23, 95% confidence interval 0.08-0.75; P=0.014), after adjusting for age, gender, race, year of sample collection, days at risk in facility, hospitalization in preceding year, and MRSA colonization/infection in preceding year.
CONCLUSION: The prevalence of reduced OCT susceptibility has remained low, despite universal OCT bathing for extended inpatient care. However, the rate of reduced CHG susceptibility was high. OCT exposure was not associated with reduced OCT susceptibility in MRSA.
Participation in this genetics study requires participants to answer some questions online, about eating behaviors (about 15-30 minutes) and to provide a single blood sample that should take only a few minutes.

To obtain the blood sample, investigators will mail you a kit which participants would take to their primary care provider or your local laboratory to have them draw a small sample of blood (about 40 mL, which is less than three tablespoons). The study is also working with a mobile phlebotomy company that can come to your home or location of your choice to draw your blood and ship it at no cost to you. Once the sample is drawn, participants or the mobile phlebotomist will place it in a box and contact FedEx for pick up. There is no cost for the FedEx shipment. Participants will also fill out the reimbursement form and send it and the receipt to our office. Investigators will reimburse participants for the cost of the blood draw. The samples will be studied directly or reprogrammed prior to further study.
The invention provides a preparation method of hydrophobic modified sodium alginate amphiphilic copolymer colloid particles. The method is characterized in that sodium alginate is used as the raw material, lower alcohol acid (lactic acid or glycollic acid) is added in a sodium alginate solution and reactes continuously for 24h at the normal temperature. The lower alcohol acid is polycondensed into a low molecular chain segment, and is simultaneously directly added into the sodium alginate chain to obtain hydrophobic modified sodium alginate amphiphilic copolymer colloid particles. Then ibuprofen is added into the colloidal solution, after uniform dispersion, the mixture of the ibuprofen and the colloidal solution are dropped into a calcium chloride solution to obtain a ''ball in ball'' product carrying the ibuprofen. The diameter of big balls is 1.5mm. The drug carrying microspheres can greatly improve thedrug loading capacity of hydrophobic medicament. In a release process, the hydrophobic medicament has obvious obvious pH responsiveness and slow releasing effect. In the preparation method of the invention, the raw material cost is low; the synthetic method is a ''one step method''; the synthesis is simple; expensive materials and complex process are avoided; the synthesis is directly finished in the solution; any organic solvent is not used in the preparation of the microspheres and in the whole use process; and the preparation method is free of toxin and is environmentally-friendly. The products can be biodegradable and have good application prospect.
PURPOSE: To report a very rare and atypical case of an elderly Caucasian female patient who developed perilesional multiple polypoidal choroidal vasculopathy (PCV) as a probable complication of choroidal osteoma (CO), associated to preretinal neovascular membrane overlying the lesion.
METHODS: Observational case report.
CASE OBSERVATION: A 60-year-old Caucasian woman presented with blurred vision in her right eye (RE). Fundus examination revealed a round white-yellowish calcified deep lesion in the juxta-papillary superior area, measuring 4 disc-diameters, with well-defined scalloped margins and an irregular surface. B-scan ultrasonography and orbital tomography confirmed the diagnosis of choroidal osteoma (CO). Further investigation with multimodal imaging including infracyanine green angiography, fluorescein angiography, swept source optical coherence tomography and angiography highlighted the presence of multiple aneurysmal choroidal dilations around the CO, corresponding to PCV. We also noted the presence of a preretinal neovascular membrane overlying the CO. The patient was monitored with regular follow-up since no signs of activity were detected on multimodal imaging.
CONCLUSION: Our case report represents an exceptional and atypical association between pre-retinal neovascularization, PCV and choroidal osteoma. While the mechanisms underlying the development of PCV and pre-retinal neovascularization in the setting of CO are not well understood, it is imperative for ophthalmologists to recognize this association as a potential cause of sudden vision loss in patients with CO, and to consider appropriate diagnostic and management strategies.
PURPOSE: Shear-wave elastography (SWE) provides quantitative and absolute metrics for analyzing the elasticity of soft tissues. Despite the anterior scalene muscle (AS) is a key structure in patients with neck pain and nerve compressive syndromes, the majority of SWE studies only included asymptomatic subjects. This study aimed to analyze the Young's modulus and shear wave speed test-retest reliability in a sample of patients with neck pain symptoms to characterize the AS stiffness.
METHODS: A diagnostic accuracy study acquiring a set of ultrasound images at C7 level in 42 patients with mechanical neck pain by one experienced examiner. After blinding the participants' identity, trial and side, the Young's modulus and shear wave velocity were measured by an independent experienced rater in randomized order. Intra-class correlation coefficients (ICC), standard error of measurement (SEM), minimal detectable changes (MDC) and coefficient of variation (CV%) were calculated.
RESULTS: The sample reported moderate pain intensity (5.9/10 points) and disability (17.38/100 points). AS stiffness metrics assessed showed no significant differences between males and females, left and right side nor painful and non-painful side. (all, p > 0.05). Intra-examiner reliability was excellent for calculating the Young's modulus for shear wave speed (ICC > 0.90).
CONCLUSION: The results support the use of this procedure for assessing the AS stiffness in populations with mechanical neck pain as excellent reliability estimates were obtained. However, future research should analyze case-control differences and the association between SWE metrics with clinical severity indicators.
The pharmaceutical composition according to the present invention comprises adenine, carnitine and cyanocobalamin, and the present invention provides a pharmaceutical composition capable of ensuring the stability of adenine by using a blocking agent or a blocking structure, and a method for preparing the same. The pharmaceutical composition according to the present invention can ensure the stability of adenine so that the content of adenine is maintained at 95% or more after 6 months in a stability test under accelerated conditions (40. + -. 2 ℃/75. + -. 5% RH).
Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
PURPOSE: A composition containing a Prunella vulgaris var. lilacina extract is provided to ensure antioxidation and to prevent and treat diabetes complication. CONSTITUTION: A pharmaceutical composition which suppresses synthesis of AGEs(advanced glycation end products) contains 0.1-50 wt% of a Prunella vulgaris var. lilacina extract as an active ingredient. The extract is prepared using water. The pharmaceutical composition suppresses synthesis of AGEs and prevents and treats diabetes complication. The pharmaceutical composition prevents and treats diseases selected from Alzheimer's disease, uremia, microangiopathy, cataract, or Parkinson's disease.
The present invention relates to continuous spray medications involving the scalp, such as minoxidil, finesteride, copper peptides, DHT inhibitors and androgen receptor blockers, for example, in an amount sufficient to stimulate or maintain hair growth. The scalp medication is disposed within a pharmacologically acceptable carrier solution. In further embodiments, the spray scalp medication is dispensed within a product bag containing the medication in liquid form. The product bag is disposed within a container and includes a sheet of gas impervious material having a barrier layer therein. A gaseous propellant is also disposed within the container and is substantially separated from the medication. The valve assembly is selectively operated to produce a fine mist of said medication which is non-chilling, continuous and even.
BACKGROUND: After craniectomy, autologous bone flaps may be stored using wet or dry cryopreservation. After brain edema subsides, they are replaced during an operation termed cranioplasty. Cranioplasty is associated with 15% infection incidence.
METHODS: We conducted a retrospective comparison of infection outcomes between wet and dry cryopreservation of cranioplasty bone flaps. Historically, bone flaps were stored utilizing wet cryopreservation-bone flap storage in 1 L of lactated Ringer's solution containing 80 mg gentamicin and 2 g nafcillin in a sterile plastic container secured in an unsterile plastic bag. Our newer dry cryopreservation protocol involved storage in gauze soaked in 80 mg gentamicin and 2 g nafcillin within a 3-layer sterile bag system.
RESULTS: A total of 119 autologous bone flaps were included, with median follow-up of 3.9 months from cranioplasty. Overall, 10.9% became infected, requiring subsequent surgery; 18.4% of 49 bone flaps stored using wet cryopreservation became infected compared with only 5.7% of 70 dry cryopreservation bone flaps (P = 0.038; relative risk [RR] 0.311; absolute risk reduction 12.7%). Tobacco use (P = 0.076; RR 3.17) was not associated with increased infection risk. Infection incidence was similar for traumatic craniectomy indications compared to the other indications (12.0% trauma vs. 10.1% other; P = 0.750). On average, infected cranioplasty patients spent 8.5 more days hospitalized and faced increased risk of additional complications.
CONCLUSIONS: Dry cryopreservation significantly decreases infection after cranioplasty when compared with wet cryopreservation, and this mitigates additional morbidity, mortality, and costs attributable to cranioplasty infection. Other nonmodifiable risk factors for cranioplasty infection were identified.
Adverse reactions have been very common in virtually all series of patients treated with amiodarone for ventricular arrhythmias with relatively large doses of drug (400 mg/day and above), occurring in about three-fourths of all patients and causing discontinuation in 7 to 18%. The most serious reactions are pulmonary toxicity, exacerbation of arrhythmia, and rare serious liver injury (see WARNINGS), but other adverse effects constitute important problems. They are often reversible with dose reduction or cessation of amiodarone treatment. Most of the adverse effects appear to become more frequent with continued treatment beyond six months, although rates appear to remain relatively constant beyond one year. The time and dose relationships of adverse effects are under continued study. 

Neurologic problems are extremely common, occurring in 20 to 40% of patients and including malaise and fatigue, tremor and involuntary movements, poor coordination and gait, and peripheral neuropathy; they are rarely a reason to stop therapy and may respond to dose reductions or discontinuation (see PRECAUTIONS). There have been spontaneous reports of demyelinating polyneuropathy.

Gastrointestinal complaints, most commonly nausea, vomiting, constipation, and anorexia, occur in about 25% of patients but rarely require discontinuation of drug. These commonly occur during high-dose administration (i.e., loading dose) and usually respond to dose reduction or divided doses.

Ophthalmic abnormalities including optic neuropathy and/or optic neuritis, in some cases progressing to permanent blindness, papilledema, corneal degeneration, photosensitivity, eye discomfort, scotoma, lens opacities, and macular degeneration have been reported (see WARNINGS).

Asymptomatic corneal microdeposits are present in virtually all adult patients who have been on drug for more than 6 months. Some patients develop eye symptoms of halos, photophobia, and dry eyes. Vision is rarely affected and drug discontinuation is rarely needed.

Dermatological adverse reactions occur in about 15% of patients, with photosensitivity being most common (about 10%). Sunscreen and protection from sun exposure may be helpful, and drug discontinuation is not usually necessary. Prolonged exposure to amiodarone occasionally results in a blue-gray pigmentation. This is slowly and occasionally incompletely reversible on discontinuation of drug but is of cosmetic importance only.

Cardiovascular adverse reactions, other than exacerbation of the arrhythmias, include the uncommon occurrence of congestive heart failure (3%) and bradycardia. Bradycardia usually responds to dosage reduction but may require a pacemaker for control. CHF rarely requires drug discontinuation. Cardiac conduction abnormalities occur infrequently and are reversible on discontinuation of drug.

The following side-effect rates are based on a retrospective study of 241 patients treated for 2 to 1,515 days (mean 441.3 days).
PROBLEM TO BE SOLVED: To prepare a hairdressing composition capable of restraining hair stickiness, capable of imparting gloss and smoothness to the hair, and useful for a hair foam or the like not including silicone oil or the like by adding a predetermined quantity of seaweed extract to Jojoba alcohol from natural products. SOLUTION: This hairdressing composition comprises (A) N- methacroyloxyethylN, N-dimethylammonium α-N-methylcarboxybetaine/alkyl methacrylate copolymer, (B) Jojoba alcohol (C) seaweed extract. It is pref. that 0.001-0.5 pts.wt. the component B is included based on 1 pt.wt. the component A, that 0.05-10 pts.wt. the component C is included based on 1 pt.wt. the component B and that the component B is obtained by reducing yellow, transparent oily liquid oil from Jojoba Simmondsia chinensis dried seeds with metallic sodium.
The invention discloses cefalexin-probenecid compound sustained release tablets and a preparation method thereof. Each sustained release tablet comprises the following components in parts by weight: 5-8 parts of cefalexin, 5-8 parts of probenecid and 20-25 parts of pharmaceutic adjuvant. The preparation method of the sustained release tablets comprises the steps of material preparation, granulation, granule arrangement and tabletting. According to the cefalexin-probenecid compound sustained release tablets and the preparation method thereof, two medicines namely the cefalexin and the probenecid are organically combined together to prepare the sustained release tablets, and the dosage of the pharmaceutic adjuvant is reduced to the greatest extent. The synergistic effect between the cefalexin and the probenecid is obvious, the probenecid serves as unilateral sustained release tablets to strengthen the effect of penicillin, 0.5g of the probenecid is taken for four times every day, namely 2g of the probenecid is taken every day; according to the sustained release tablets provided by the invention, the effect can be achieved by needing only 1.4g of the probenecid every day, so that the dosage of bulk pharmaceutical chemicals is reduced. The cefalexin-probenecid compound sustained release tablets are simple in formulation, stable in process, unlikely to stick and high in weight uniformity, and the release rate meets requirements.
PURPOSE: A radiation sterilizing method of skin regeneration organization or ligament renewal tissue is provided to prevent transformation or degradation of physical properties of skin or ligament transplant material. CONSTITUTION: A radiation sterilizing method of skin regeneration organization or ligament renewal tissue comprises the following steps: adding polyglutamic acid to a transplant material; and suppressing transformation of the physical properties of skin or ligament transplant material by irradiating radiation. The radiation irradiation uses one of gamma-ray, electron beam and X-ray at the absorption dose of 1-100kGy. The skin transplant material is allogenic skin transplant material or heterodermic skin transplant material. The ligament transplant material is allogenic ligament transplant material or different kind ligament transplant material. [Reference numerals] (AA) Non-irradiation; (BB) 30kGy irradiation; (CC) Non-processed area; (DD) Epidermis; (EE) Dermis; (FF) Striatum papillae of dermis; (GG) Straiatum reticulum of dermis; (HH) Polyglutamic acid added area